Previous 10 | Next 10 |
Lyra Therapeutics press release (NASDAQ:LYRA): FY GAAP EPS of -$3.35 misses by $0.23. Cash and cash equivalents as of December 31, 2021 were $45.7 million, compared with $58.1 million as of September 30, 2021. Shares -1.18% PM. For further details see: Lyra Therapeutics GAAP EPS of -$3....
Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Treated first patient in pivotal Phase 3 ENLIGHTEN program for surgically naïve chronic rhinosinusitis patients Initiated BEACON Phase 2 trial for LYR-220 in chro...
Lyra Therapeutics Appoints Jim Tobin to Board of Directors Biopharmaceutical leader brings decades of expertise with C-suite tenures at Boston Scientific, Biogen and Baxter International PR Newswire WATERTOWN, Mass. , March 7, 2022 /PRNewswire/ -- Lyra Therap...
Lyra Therapeutics (NASDAQ:LYRA) enrolled the first patient in a phase 3 ENLIGHTEN I trial of LYR-210 in adult patients with chronic rhinosinusitis (CRS). The company said LYR-210 is designed as an alternative to sinus surgery. The ENLIGHTEN program will consist of two, staggered phase 3 studi...
Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients PR Newswire WATERTOWN, Mass. , Feb. 28, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics ...
The following slide deck was published by Lyra Therapeutics, Inc. in conjunction with this event. For further details see: Lyra Therapeutics (LYRA) Investor Presentation - Slideshow
Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman Recent President and Chief Executive Officer of Kadmon brings vast experience leading and scaling late-stage and commercial biopharmaceutical companies PR Newswire WATERTOWN, Mass. , Feb. 17...
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients Company also announces initiation of BEACON clinical study of LYR-220 in previously operated chronic rhinosinusitis patients LYR-210 a...
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences PR Newswire WATERTOWN, Mass. , Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform...
Lyra Therapeutics, Inc. (LYRA) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Stephanie Marks - Argot Partners Maria Palasis - President and CEO Jason Cavalier - CFO Robert Kern - Chief Medical Officer Corinne Noyes - SVP-Commercial Strategy & Market ...
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...